Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoCell Transplantation for Idiopathic Parkinson's Disease
NCT05094011Phase 1Not yet recruiting
- Sponsor
- Taiwan Mitochondrion Applied Technology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of MitoCell in Parkinson's disease (PD), sponsored by Taiwan Mitochondrion Applied Technology Co., Ltd. Primary endpoints: Grading of Adverse Events at 48 weeks, Routine physical examinations at 48 weeks and 5 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
MitoCell
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05094011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094011.